TaiwanJ Pharmaceuticals Co., Ltd. (6549.TWO)
TWD 8.03
(-0.5%)
TWD 8.03
(-0.5%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -821 Thousand | -21.07 Million | -10.04 Million | -41.27 Million | 16.85 Million |
| Net Income | -3.77 Million | -92.46 Million | -10.31 Million | -42.45 Million | -5.08 Million |
| Depreciation & Amortization | 2.01 Million | 76.46 Million | 1.15 Million | 1.41 Million | 21.92 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 1.38 Million | 588 Thousand | -14 Thousand | 718 Thousand | 2.4 Million |
| Change in working capital | 4.34 Million | -15.91 Million | 1.26 Million | -863 Thousand | 2.59 Million |
| Other non-cash items | -2.49 Million | -483 Thousand | -25 Thousand | -60 Thousand | -4.98 Million |
| Investing Cash Flow | -351 Thousand | -557 Thousand | 38 Thousand | 10.86 Million | -14.57 Million |
| Investments in PPE | -1.44 Million | -1.22 Million | - | -1.43 Million | -1.46 Million |
| Acquisitions | - | - | - | - | - |
| Investment purchases | - | - | - | - | -12.21 Million |
| Sales/Maturities of investments | - | - | - | 12.21 Million | - |
| Other Investing Activities | -1.42 Million | 175 Thousand | 38 Thousand | 10.86 Million | -1.58 Million |
| Financing Cash Flow | -687 Thousand | -561 Thousand | -559 Thousand | 65.3 Million | -1.28 Million |
| Debt repayment | -687 Thousand | -561 Thousand | -559 Thousand | -699 Thousand | -1.28 Million |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | - | - | - | 66 Million | - |
| Other Financing Activities | -687 Thousand | - | - | 66 Million | - |
| Accounts receivables | 4.6 Million | -15.35 Million | - | - | - |
| Accounts payables | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other working capital | 627 Thousand | -423 Thousand | 1.15 Million | -616 Thousand | 2.59 Million |
| Cash at beginning of period | 60.68 Million | 82.87 Million | 93.44 Million | 58.55 Million | 57.56 Million |
| Cash at end of period | 58.82 Million | 60.68 Million | 82.87 Million | 93.44 Million | 58.55 Million |
| Capital Expenditure | -1.44 Million | -1.22 Million | - | -1.43 Million | -1.46 Million |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | -1.85 Million | -22.19 Million | -10.56 Million | 34.89 Million | 990 Thousand |
| Free Cash Flow | -2.26 Million | -22.29 Million | -10.04 Million | -42.7 Million | 15.38 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -4.84 Million | -4.84 Million | -9.03 Million | -3.77 Million | -9.03 Million | 6.01 Million |
| Depreciation & Amortization | 490.5 Thousand | 490.5 Thousand | 527.5 Thousand | 2.01 Million | 527.5 Thousand | 478.5 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 50 Thousand | - | 345.5 Thousand | 1.38 Million | 345.5 Thousand | 346 Thousand |
| Change in working capital | -55.5 Thousand | -619 Thousand | -132.5 Thousand | 4.34 Million | -132.5 Thousand | 2.74 Million |
| Other non-cash items | -1.18 Million | -573 Thousand | 469.5 Thousand | -2.49 Million | 469.5 Thousand | -2.17 Million |
| Investing Cash Flow | -7.91 Million | -7.91 Million | 43.5 Thousand | -351 Thousand | 43.5 Thousand | -219 Thousand |
| Investments in PPE | - | - | - | -1.44 Million | - | -720.5 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -17.08 Million | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -7.91 Million | -7.91 Million | 43.5 Thousand | -1.42 Million | 43.5 Thousand | 501.5 Thousand |
| Financing Cash Flow | -174 Thousand | -174 Thousand | -172.5 Thousand | -687 Thousand | -172.5 Thousand | -171 Thousand |
| Debt repayment | - | - | - | -687 Thousand | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -174 Thousand | -174 Thousand | -172.5 Thousand | - | -172.5 Thousand | -171 Thousand |
| Accounts receivables | 240 Thousand | - | - | 4.6 Million | - | 2.3 Million |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | -55.5 Thousand | -619 Thousand | -132.5 Thousand | 627 Thousand | -132.5 Thousand | 446 Thousand |
| Cash at beginning of period | 58.82 Million | - | - | 60.68 Million | - | - |
| Cash at end of period | -13.63 Million | -13.63 Million | -7.95 Million | 58.82 Million | -7.95 Million | 7.02 Million |
| Capital Expenditure | - | - | - | -1.44 Million | - | -720.5 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -72.46 Million | -13.63 Million | -7.95 Million | -1.85 Million | -7.95 Million | 7.02 Million |
| Free Cash Flow | -5.54 Million | -5.54 Million | -7.82 Million | -2.26 Million | -7.82 Million | 6.69 Million |
GXAI
6625
412540
RWCB
IDNT
6198